Track topics on Twitter Track topics that are important to you
LAVAL, QUEBEC -- (Marketwired) -- 08/13/15 -- ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has closed the acquisition of Emergent BioSolutions' ("Emergent") plasma collection center located in Winnipeg, Canada following completion of closing conditions.
The plasma collection center has now started to operate under ProMetic's ownership following the grant and receipt of the regulatory licenses by and from the requisite regulatory authorities. ProMetic's plasma collection center is an FDA and Health Canada licensed plasma collection facility conveniently located in close proximity to the existing Emergent Winnipeg based cGMP manufacturing facility, which provides ProMetic with up to 250,000 liters of annual plasma processing capacity.
"The closing of the acquisition of our first plasma collection center is yet another milestone achievement in our corporate strategy towards becoming a vertically integrated biopharmaceutical company. This center provides us with readily accessible specialty plasma necessary to bring to market innovative plasma derived therapeutic solutions," declared Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "The opening of our first ProMetic owned plasma collection center will play a key role in complementing our growing network of US based plasma suppliers while allowing us to better manage our plasma supply chain," added Mr. Laurin.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of both the plasma-derived and small molecule products are under development for orphan drug indications. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe and Asia.
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2014, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.Contacts: ProMetic Life Sciences Inc. Pierre Laurin President and CEO 450.781.0115 ProMetic Life Sciences Inc. Frederic Dumais Senior Director, Communications & Investor Relations 450.781.0115 NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...